Navigation Links
Robert Haynes To Lead Licensing As VR Laboratories' Senior Vice President Product Introduction And Licensing
Date:11/14/2012

BONITA SPRINGS, Fla., Nov. 14, 2012 /PRNewswire-iReach/ -- VR Laboratories LLC today announced the appointment of Robert Haynes as Senior Vice President, Product Introduction and Licensing. Haynes brings more than 25 years of management and executive experience in pharmaceutical and biotechnology product development, partnering, and global commercialization.  Most recently, Haynes led the Alliance Management and New Product Planning departments at Human Genome Sciences (HGS). At HGS Haynes also led the development and global commercialization of the company's lead product - Benlysta®  - taking it from discovery through clinical development and successful commercialization around the world as the first new therapy approved for lupus in over 50 years. In addition to Benlysta Mr. Haynes has held leadership roles for numerous successful brands including Strattera®, Evista®, Axid®, Prozac®, and Ceclor®.

(Photo: http://photos.prnewswire.com/prnh/20121114/CG13570)

"Robert brings extensive experience in the pharmaceutical and biotechnology industries to VR and we look forward to his leadership in advancing our extensive pipeline internally and with partners across the globe," says Jeff Kottkamp, CEO of VR Laboratories. "As an innovative natural products company, we will benefit from his experience, developing, launching, commercializing, and partnering assets in all stages across many different therapeutic areas."

Haynes' background includes a wide variety of commercial management positions in both the pharmaceutical and biotechnology industries. This includes business development and licensing, strategic marketing, new product development, global brand and portfolio management, market research, and sales. He began his career with Eli Lilly and company in 1988 following receiving his Masters of Business Administration degree from the Owen Graduat
'/>"/>

SOURCE VR Laboratories www.vr-laboratories.com
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
2. Fortis Vice President of Nursing Robert Anders Named Academy of Nursing Education Fellow by National League for Nursing
3. Engineer Robert J. Wood to receive NSFs Alan T. Waterman Award
4. Robert Farrell Joins Bionovos Board of Directors
5. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
6. LLSs Lead Therapy Acceleration Program in MDS Gets Boost from Major Industry Licensing Agreement
7. Sangui and SastoMed Complement Licensing Agreement in View of Increasing Sales Success
8. Life Technologies Signs Licensing Agreement with iPS Academia Japan for Global Patent Portfolio Rights to Induced Pluripotent Stem Cell Technology
9. IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
10. Aviir Diagnostic Laboratories Secures $8 Million In Funding From Silicon Valley Bank
11. Medical Diagnostic Laboratories, L.L.C. Announces a Complimentary Reflex Test to Determine Azithromycin Resistance in Chlamydia Trachomatis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... Aug. 31, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... PBT.U), is pleased to announce that its wholly owned ... lead candidate, PPL-003, to an Investigational New Drug (IND) ... and uveitis.  PPL recently completed a study in a ... solution achieved highly significant efficacy and a more rapid ...
(Date:8/31/2015)... SHANGHAI , Aug. 31, 2015 /PRNewswire/ ... next-generation antibiotics, today announced positive top-line results from ... lead drug candidate MRX-I. MRX-I is an oral ... as MRSA and VRE, while offering physicians and ... than currently available oxazolidinone agents. ...
(Date:8/31/2015)... -- Trimb Healthcare AB ("Trimb") today announced that it ... ("YouMedical"), a Dutch OTC company with operations in key ... EUR 16 million, with solid growth and leading brands ... to build a leading international OTC company, and this ... gives us a stronger North European OTC platform, from ...
(Date:8/31/2015)... ... 31, 2015 , ... There’s a new treatment option for excessive menstrual bleeding ... new FDA approved system in the last 14 years, and the only endometrial ablation ... bleeding) rate of 66%, the high Patient Satisfaction rate of 98%, and the fastest ...
Breaking Biology Technology:Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 2Portage's PPL will advance its lead candidate PPL-003 to an IND for dry eye disease and uveitis 3MicuRX Reports Positive Top-Line Results In Phase 2 Clinical Trial For Novel Antibiotic MRX-I In Complicated Skin And Soft Tissue Infections 2U.S. FDA Approves Minerva Endometrial Ablation System 2U.S. FDA Approves Minerva Endometrial Ablation System 3
... July 21, 2011 The U.S. Food & Drug ... a clinical trial for gene therapy for a rare ... and London, this trial based on preclinical research performed ... gene therapy product, is now going to be launched ...
... July 21, 2011 Advanced Cell Technology, Inc. ("ACT"; ... medicine, announced today that it has entered into an ... Biotech"), a leading South Korea-based biotechnology company, designed to ... venture, Stem Cell & Regenerative Medicine International (SCRMI).  Under ...
... DURHAM, N.C. Researchers at Duke University Medical Center ... of Chlamydia , the bacteria responsible for the ... States. The team, which included Duke University ... the bacteria,s self-defense mechanisms. The therapies that ...
Cached Biology Technology:Genethon and Children's Hospital Boston Get FDA approval for a Wiskott Aldrich Gene Therapy Trial 2Genethon and Children's Hospital Boston Get FDA approval for a Wiskott Aldrich Gene Therapy Trial 3Genethon and Children's Hospital Boston Get FDA approval for a Wiskott Aldrich Gene Therapy Trial 4Genethon and Children's Hospital Boston Get FDA approval for a Wiskott Aldrich Gene Therapy Trial 5ACT Obtains Exclusive License for Hemangioblast Technology in North America 2ACT Obtains Exclusive License for Hemangioblast Technology in North America 3ACT Obtains Exclusive License for Hemangioblast Technology in North America 4ACT Obtains Exclusive License for Hemangioblast Technology in North America 5Newly designed molecule blocks chlamydia bacteria 2Newly designed molecule blocks chlamydia bacteria 3
(Date:8/28/2015)... -- According to a new market research ... (Pen & Paper Based, Hosted, Biometrics), Service, Application (Clinical ... Vertical and Region - Global Forecast to 2020", published ... from USD 2.4 Billion in 2015 to USD 7.5 ... (CAGR) of 25.6% from 2015 to 2020. ...
(Date:8/24/2015)... August 24, 2015 The consulting company ... largest biometrics manufacturer DERMALOG and its customized solutions and products ... Biometrics Company of the Year Award". DERMALOG is particularly successful ... .   -Cross reference: Picture is available at ... On Thursday evening, in South Africa,s ...
(Date:8/20/2015)... 20, 2015   Sensory, Inc ., a ... user experience and security of consumer electronics through ... that its TrulySecure™ is the first ... be FIDO Certified™. The FIDO (Fast ... the FIDO UAF (Universal Authentication Framework) 1.0 specifications, ...
Breaking Biology News(10 mins):Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 2Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 3Cognitive Assessment and Training Market Worth 7.5 Billion USD by 2020 4Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 2Frost & Sullivan Honors DERMALOG with Biometrics Prize for Achievements in Africa 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5
... STATION Researchers at Texas A&M University have confirmed for ... off the Texas coast for at least the past 23 ... to marine life in the area. Steve DiMarco, associate ... dead zones in the Gulf of Mexico for more than ...
... fresh evidence that urbanization in the United States threatens the ... six-year study also refutes one of the most widely accepted ... kinds of birds. Most ecologists have assumed that common ... and raccoons were destroying eggs or killing young birds ...
... Md., April 1, 2008 The U.S. Pharmacopeial (USP) ... dissolution variability of USP Prednisone Lot P Reference Standard ... less variability in USP Prednisone Lot P tablets than ... dosage forms plays a critical role in drug manufacturing ...
Cached Biology News:Researchers confirm dead zone off Texas coast since 1985 2Some migratory birds can't find success in urban areas, study finds 2Some migratory birds can't find success in urban areas, study finds 3Prednisone tablets less variable than marketed drugs 2
Homo sapiens 4-aminobutyrate aminotransferase Antigen: Recombinant Protein...
... Serum • Mouse serum is collected off the clot ... weeks of age. Available Anticoagulants: N-02: ... K2EDTA N-08: Potassium Oxalate N-10: ... ACD N-07: CPD N-09: ...
One-step, microplate or cuvet, colorimetric, linear detection range 8 mg/dL to 300 mg/dL. Procedure: 5 min....
RABBIT ANTI HUMAN TRRAP (CT) Immunogen: Recombinant C-terminal kinase-related domain of human TRRAP....
Biology Products: